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Abstract
We report a genome-wide association study of melanoma, conducted by GenoMEL, of 2,981 
cases, of European ancestry, and 1,982 study-specific controls, plus a further 6,426 French and 
UK population controls, all genotyped for 317,000 or 610,000 SNPs. The analysis confirmed 
previously known melanoma susceptibility loci. The 7 novel regions with at least one SNP with 
p<10−5 and further local imputed or genotyped support were selected for replication using two 
other genome-wide studies (from Australia and Houston, Texas). Additional replication came 
from UK and Dutch case-control series. Three of the 7 regions replicated at p<10−3: an ATM 
missense polymorphism (rs1801516, overall p=3.4×10−9); a polymorphism within MX2 (rs45430, 
p=2.9×10−9) and a SNP adjacent to CASP8 (rs13016963, p=8.6×10−10). A fourth region near 
CCND1 remains of potential interest, showing suggestive but inconclusive evidence of replication. 
Unlike the previously known regions, the novel loci showed no association with nevus or 
pigmentation phenotypes in a large UK case-control series.
Cutaneous melanoma is predominantly a disease of fair-skinned individuals. Risk factors 
include a family history1, certain pigmentation phenotypes (notably the presence of fair skin, 
blue or green eyes, blond or red hair, sun sensitivity or an inability to tan2-5) and increased 
numbers of melanocytic nevi6,7. We previously reported Phase 1 of a genome-wide 
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association (GWA) study of melanoma based on the Illumina 317k array8. This reinforced 
the importance of these genetically-determined melanoma-associated phenotypes, by 
showing the major common genetic determinants of risk in the populations considered were 
the MC1R locus (associated with red hair, freckling and sun sensitivity)4,5,9,10, tyrosinase 
(TYR) gene variants which code for skin color11 and a region near CDKN2A and MTAP 
which is associated with number of melanocytic nevi8,12. Furthermore we confirmed the 
importance of a haplotype spanning the agouti signaling protein locus (ASIP)11,13 and a 
second locus determining nevus count variation at 22q13 identified by a GWA study of 
nevus count12.
Both Phase 1 and Phase 2 of this study were carried out by the GenoMEL Consortium, a 
collaboration focusing on genetic susceptibility to melanoma. The study utilised samples 
collected by GenoMEL participants across populations of European ancestry living at 
different latitudes. In total, 14 GenoMEL groups contributed DNA samples from cases and 
controls of European (or Israeli) ethnicity (Supplementary Table 1). Phase 1 was based on 
1,650 cases from Australian and European populations chosen to have a phenotype argued 
to “enrich” for genetic susceptibility (early onset, multiple primaries, or modest family 
history of melanoma). In Phase 2 a further 1,523 cases (1,211 of whom are genetically 
enriched: 532 with a family history, 277 with multiple primaries but no family history, and 
402 with early disease onset but no multiple primaries or family history) and 1,112 controls 
were genotyped using the denser Illumina 610k array (see Supplementary Note). To 
optimise power for novel gene identification we combined the data from the two phases and 
performed an overall analysis. The Australian data used in Phase 1 were dropped from the 
combined Phase 1 + Phase 2 analysis as these samples are included in the Australian GWA 
study which formed one of the replication studies. After quality control was applied to SNPs 
and samples (see Supplementary Note), including Principal Components Analysis (PCA) to 
identify samples of non-European ethnicity (Supplementary Figure 1), the analysis utilised 
2,804 cases (2,692 European and 112 Israeli) and 1,835 controls from GenoMEL studies and 
5,783 controls from France and the UK Wellcome Trust Case-Control Consortium 
(WTCCC). A trend test, stratified by geographical region, was applied to each SNP (see 
Online Methods, also Figure 1). Little evidence was found of population stratification 
(λ=1.06, see Supplementary Figure 5).
Strong evidence was found for the previously identified loci, (Supplementary Table 2, 
Supplementary Figures 2 and 3)8,11-18 and another pigmentation gene, SLC45A2, already 
reported to be associated with melanoma risk15. SLC45A2 is involved in melanosome 
maturation and pigmentation. The rs35390 SNP identified here is associated with 
melanoma15 and with variation in hair color15,20, in accordance with the observed pattern of 
known melanoma pigmentation risk factors2-5.
We also confirmed a role for SNP rs401681 in the region of TERT and CLMPT1L, which 
has also previously been shown to modify melanoma risk18 (Supplementary Table 2, 
Supplementary Figures 2 and 3)8,11-16,21. The confirmation of the SNP follows reported 
associations with risk of basal cell carcinomas, hematological malignancies and cancer of 
the bladder, cervix, lung, pancreas and prostate18,22. It was originally reported that the 
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pattern of risk for melanoma was in the opposite direction to that for other cancers18, and we 
confirm this observation.
Seven further regions showed evidence of association with melanoma susceptibility (Table 1 
and Supplementary Table 3). Replication was sought from two other GWA studies for the 
SNPs with the strongest evidence, preferentially SNPs common to all arrays. In regions with 
no SNP common to all platforms, we followed up both our top genotyped SNPs and the 
most significant imputed SNPs which had been genotyped in the replication studies. Further, 
these SNPs were genotyped in a replication sample set from the UK and the Netherlands 
(1,579 cases and 2,036 controls in total, see Supplementary Note). Table 1 contains the 
evidence from both the hypothesis-generating and replication datasets. Of these seven 
regions, three (on chromosomes 2 (rs13016963), 11 (rs1801516) and 21) showed strong 
evidence of replication (p<10−3), three (on chromosomes 2 (rs10932444), 12 and 13) 
showed no evidence of replication and one (on chromosome 11 (rs1485993)) showed 
marginal evidence of replication. Three of the loci showed overall combined evidence of 
association at p<5×10−8, based on the fixed effects meta-analysis.
The CASP8 region (chromosome 2) contains a number of SNPs showing evidence for 
association with melanoma risk; because of the lack of overlap in the SNPs across arrays, 
we report multiple SNPs either genotyped or imputed across platforms, all of which show 
evidence of association (Table 1, Supplementary Table 3, Figure 2). The strongest evidence 
for a single SNP is for rs700635 (p=2.4×10−9, OR=1.15 overall). All the SNPs are in the 
region of CASP8, which codes for a member of a family of proteases that play a critical role 
in the control of cell proliferation by inducing apoptotic cell death, making them candidate 
cancer susceptibility genes. A recent meta-analysis23 of 3 polymorphisms in CASP8 found 
that individuals with one or more copies of the D302H variant have a decreased risk of 
multiple types of cancer. In this study, the D302H variant could be imputed, but showed 
only marginal evidence of association (p=0.05), suggesting this is not a variant for 
melanoma. The evidence for melanoma risk was consistent across populations (Figure 3).
The ATM SNP rs1801516 (chromosome 11) (Table 1, Supplementary Table 3, Figure 2) is a 
missense mutation (D1853N, G > A) in a gene that codes for a protein which repairs double 
strand DNA breaks; association has been postulated between ATM and a number of cancer 
types24. For melanoma, the A allele is protective (p=3.4×10−9, OR=0.84 overall). Overall 
the evidence for melanoma is consistent across populations and case type, with no evidence 
of heterogeneity (Figure 3).
The third replicated region, around MX2 (chromosome 21), showed consistent effect sizes 
across the replication datasets (Table 1, Supplementary Table 3, Figure 2) and across 
populations (Figure 3). The SNP followed up in the replication study is rs45430 
(p=2.9×10−9, OR=0.88 overall), which is intronic to MX2 and has not previously been 
associated with cancer susceptibility.
A fourth region, adjacent to CCND1 (chromosome 11), a proto-oncogene which is a key 
regulator of cell cycle progression, showed consistent effect sizes across all the replication 
sets (Table 1, Supplementary Table 3, Supplementary Figure 4), with best overall replication 
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p-value of 0.011. However the replication sets produced a notably smaller OR (1.08) than 
the discovery set (1.19) (I2=0.507). This is potentially due to the well known Winner's Curse 
effect25 that causes the initial discovery set to overestimate the OR, leading in turn to a 
discrepancy between the overall p-value based on fixed effects and random effects meta-
analysis (p=1.7×10−7 and p=0.00046 respectively). Thus, while we have strong support from 
this region, the evidence cannot be considered conclusive (see Supplementary Note for 
further details). However, further support comes from the interim analysis of a recently 
completed melanoma GWA study in494 melanoma cases and 5,628 controls from the 
Nurses' Health Study and Health Professionals Follow-up Study (OR=1.18 for rs1485993, 
p=0.014, unpublished data). This gene therefore remains a strong candidate, being well 
known in melanoma carcinogenesis26.
In Phase 1 of the study, all melanoma susceptibility loci identified were associated with 
either skin pigmentation or nevus count variation8. For the case-control samples from Leeds, 
UK, detailed nevus count and pigmentation information has been obtained for cases and 
controls27. Table 2 shows the association between nevus count, pigmentation and all SNPs 
associated with melanoma. (Note that not all SNPs show convincing evidence of melanoma 
association within the Leeds case-control samples, reflecting limited power). As expected, 
MC1R, SLC45A2, IRF4 and TYR are confirmed to be associated with pigmentation, while 
the rs4911442 SNP on chromosome 20 shows strong association with pigmentation, 
increasing the evidence that ASIP truly is the focus of this hit and implicating probable 
linkage disequilibrium (LD) with variants within an ASIP regulatory region. SNPs in the 
region of CDKN2A/MTAP and PLA2G6 are associated with nevus variation. The TERT/
CLMPT1L SNP is also associated with nevus count variation, suggesting its effect on 
melanoma risk modification may be via this mechanism. We previously showed that IRF4 
had a complex relationship with nevus count and melanoma risk14, and there are suggestions 
for SNPs in the CASP8 region of a relationship between genotype and nevus count in 
controls; among cases the association is not apparent (Table 2). Finally, the SNPs in the 
ATM and MX2 regions show no association with either nevus count or pigmentation, 
suggesting alternative, unknown mechanisms, although these require evaluation in other 
populations (see Supplementary Note).
Overall, we report 3 novel loci associated with melanoma risk, which achieve an overall 
significance level of 5×10−8 based on the fixed effects meta-analysis, and a potential fourth 
locus. The power to detect SNPs with effect sizes similar to those estimated from the 
replication studies is low, and we see many more SNPs in novel regions (from across the 
genome) reaching p-values between 10−4 and 10−5 than expected (68 with MAF>0.05 
compared with an expected 46), suggesting that there may be many other genetic regions 
with a similar effect on melanoma risk (see Supplementary Note). Currently 11 loci have 
been identified (Table 2), with a suggestion that 5 of these regions act through the 
pigmentation phenotype and at least 3 through the nevus phenotype, reflecting the major 
phenotype-associated risk factors for melanoma. Interestingly, at least two of the newly 
identified loci appear to influence risk through a novel mechanism, opening up potential 
new directions for melanoma research.
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Manhattan plot of results of Cochran-Armitage (CA) trend test stratified by geographic 
region, with -log10 p-values shown. The solid horizontal line indicates a p-value of 10−5. 
Markers within 50kb of a SNP associated with melanoma are marked in black for those 
identified in a previous GWA and replicated here and marked in red if first identified in the 
current study. The y-axis is truncated at p=10−15, although three SNPs in the MC1R region 
have stronger p-values, up to 2.7×10−27, as signified by the box and arrow.
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Stratified CA trend tests for the three replicated regions on chromosomes 2, 11 and 21. The 
log10 p-values are from the CA trend test (stratified by geographical region) for genotyped 
and imputed SNPs, indicated on the left-hand vertical axis. SNPs genotyped for all samples 
are plotted as circles, SNPs imputed for all samples as crosses and SNPs genotyped for some 
samples and imputed for others (due to chip differences) as squares. The most significant 
genotyped SNP is colored purple (with its name above) and the degree of LD between that 
SNP and the others is indicated by color according to the key (red being the greatest degree 
of LD). The estimated recombination rate is given by the blue line and indicated on the 
right-hand vertical axis. The genes in the region and their positions are given underneath the 
graph. Plots produced using LocusZoom19.
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Forest plot of the per-allele OR for melanoma for SNPs in the 3 regions first identified in 
this study. Plots show the current evidence for effects by geography, in the genome-wide 
and replication samples, and by case type (family history, multiple primaries or early onset).
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